Company Description
Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests in the United States and internationally.
The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions.
It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
| Country | United States |
| Founded | 1991 |
| IPO Date | Oct 5, 1995 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 2,700 |
| CEO | Paul Diaz |
Contact Details
Address: 322 North 2200 West Salt Lake City, Utah 84116 United States | |
| Phone | 801 584 3600 |
| Website | myriad.com |
Stock Details
| Ticker Symbol | MYGN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000899923 |
| CUSIP Number | 62855J104 |
| ISIN Number | US62855J1043 |
| Employer ID | 87-0494517 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Paul J. Diaz J.D. | Chief Executive Officer, President and Director |
| Scott J. Leffler | Chief Financial Officer |
| Samraat S. Raha | Chief Operating Officer |
| Dr. Dale Muzzey Ph.D. | Chief Scientific Officer |
| Mark S. Verratti | Chief Commercial Officer |
| Natalie Munk | Senior Vice President and Chief Accounting Officer |
| Dr. Kevin Richard Haas Ph.D. | Chief Technology Officer |
| Matthew Scalo | Senior Vice President of Investor Relations |
| Jennifer L. Fox J.D. | Chief Legal Officer |
| Shereen Solaiman | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2025 | ARS | Filing |
| Apr 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 9, 2025 | DEF 14A | Other definitive proxy statements |
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 24, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Jan 15, 2025 | 8-K | Current Report |
| Dec 10, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 8-K | Current Report |